Global Biological Product Manufacturing Market Growth (Status and Outlook) 2023-2029

Global Biological Product Manufacturing Market Growth (Status and Outlook) 2023-2029

The biological product manufacturing is a complex process which produces products derived from recombinant DNA technology to develop a series of processes to manufacture therapeutic products. A biological product can be a virus, antitoxin, vaccine, blood component or derivative, allergenic product, or analogous product, or any therapeutic serum used for the treatment of a disease in humans. These biological products were developed from multicellular systems comprising of plants, animals, unicellular organisms and a mammalian cell. Biological products are composed of sugars, nucleic acids or combination of both.

LPI (LP Information)' newest research report, the “Biological Product Manufacturing Industry Forecast” looks at past sales and reviews total world Biological Product Manufacturing sales in 2022, providing a comprehensive analysis by region and market sector of projected Biological Product Manufacturing sales for 2023 through 2029. With Biological Product Manufacturing sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Biological Product Manufacturing industry.

This Insight Report provides a comprehensive analysis of the global Biological Product Manufacturing landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Biological Product Manufacturing portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Biological Product Manufacturing market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Biological Product Manufacturing and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Biological Product Manufacturing.

The global Biological Product Manufacturing market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

The biological products are produced in three ways: by developing ways to achieve commercial production of the substance to be used, by gene alteration of the molecule and finally by developing an entirely new substance. Some of the tools used by modern day researcher in the manufacturing of biological products are recombinant DNA and monoclonal antibodies. Recombinant DNA involves altering of the DNA chain of one organism with desired DNA molecule to produce a novel biological product. Monoclonal antibodies were developed from single cell cultures using cloning techniques; these were designed to fight against toxins, viruses, and cancer cells. The first genetically engineered biological product approved for use in the U.S. was a vaccine for hepatitis-B which was approved in 1986, in the same year, other biological products like therapeutic monoclonal antibodies (MAB’s) and alpha interferon’s were approved.

This report presents a comprehensive overview, market shares, and growth opportunities of Biological Product Manufacturing market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Monoclonal Antibodies
Recombinant Proteins
Growth Hormones
Beta Interferon
Therapeutic Enzymes

Segmentation by application
Hospitals
Specialized Clinics
Government Research Institutes

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Novartis
F.Hoffmann-La Roche
Merck
Bayer
Lonza
China Biologic Products
Pfizer
Sanofi
Teva Pharmaceutical Industries
Amgen

Please note: The report will take approximately 2 business days to prepare and deliver.